Published in Medical Letter on the CDC and FDA, March 12th, 2006
The company is preparing to submit the additional requested data in advance of a meeting with the FDA scheduled for the second quarter of this year. As a result, initiation of the proposed clinical efficacy trial of LEP-ETU would commence, at the earliest, in the second quarter...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.